Lancet Gastroenterology & Hepatology

Papers
(The H4-Index of Lancet Gastroenterology & Hepatology is 73. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Research in Brief1241
EASL Congress 2024431
GORD: pain, PPIs, and preciseness425
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma417
Research in Brief384
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design374
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11346
Viral hepatitis: time for action327
Lucky: Learning to Live Again327
The changing prevalence of functional constipation: why words matter288
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis248
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply242
Treatment withdrawal in Crohn's disease: slowly becoming clearer239
Immune checkpoint inhibitors in colorectal cancer: dream and reality230
Trends in alcohol-specific deaths in the UK and industry responses210
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship198
Global multi-stakeholder endorsement of the MAFLD definition194
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension185
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium185
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial182
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives182
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic182
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study179
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial174
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement173
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled172
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t169
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial168
Research in brief159
ACG 2024146
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply138
Rare cause of dysphagia in a young woman138
Has the time come for a systematic top-down approach in Crohn's disease?128
Water and sanitation for all127
The potential of ctDNA in locoregional therapies for colorectal cancer127
Bringing organ preservation closer for selected patients with rectal cancer127
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere127
Addressing the rise of early-onset colorectal cancer119
Management of portal vein thrombosis in cirrhosis114
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)112
Resmetirom for NASH: balancing promise and prudence109
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial107
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47105
Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial103
Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study102
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada98
Sex and gender in inflammatory bowel disease outcomes and research97
Long-term VEDOKIDS results: implications for practice and research97
All roads lead to the gut–brain microbiome network97
Local and systemic therapy in liver cancer: the quest for synergy96
Research in Brief95
Idiopathic gastroparesis consensus misses the patient's voice93
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study93
Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework92
Availability of point-of-care HBV tests in resource-limited settings92
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review91
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED90
Practicalities accessing precision medicine in biliary tract cancer90
Britta Siegmund: answering the big questions in IBD87
A women-focused matrix mentorship programme in gastroenterology86
Management of malignant bowel obstruction – Authors' reply86
Research in Brief85
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations85
The Year My Life Went Down the Toilet84
Robotic versus laparoscopic surgery for middle and low rectal cancer84
Lifting the minority tax in gastroenterology and hepatology83
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist82
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial81
The relationship between gastrointestinal cancers and the microbiota78
Hypovolaemic phlebotomy for hepatic resection77
Diversity in clinical trials: an opportunity and imperative for community engagement75
Managing inflammatory bowel disease: what to do when the best is unaffordable?75
Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system74
Research in Brief73
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study73
0.041170835494995